On September 6th, eight central state-owned financial enterprises unveiled plans for a capital injection aimed at replenishing their core Tier 1 capital. The recipients range across large state-owned banks, insurance companies, and policy-oriented financial institutions, bringing the total funding amount to 360 billion yuan. The move may carry considerable weight for market dynamics and long-term capital allocation.

The 360 billion yuan will be sourced from a combination of a 300 billion yuan special government bond designed for capital injections, and 60 billion yuan subscribed by the tobacco system. It is worth noting that the special treasury bond itself has yet to be issued. The Government Work Report from March outlined a plan to issue 300 billion yuan in special bonds to support capital replenishment at major state-owned commercial banks. The annual issuance schedule published in April indicated that 5-year and 7-year tranches would be launched in May and June, respectively. However, actual issuance has not taken place, and market expectations now lean toward a swifter rollout.

Drawing parallels with last year, the issuance of special bonds for capital injections is expected to progress at a rapid pace, with maturities concentrated in the 5-7 year range. The timeline in the prior year offers a useful reference: The four major banks announced the initiation of private placement processes on March 30th. Between April 24th and June 4th, four tranches of special bonds were issued, totaling 500 billion yuan, evenly split between 5-year and 7-year maturities. By June 13th to 23rd, various banks had successively announced the completion of their placements, wrapping up the entire process in just over two months.

In terms of distribution, the capital allocated to the large banks stands at 260 billion yuan and is slightly beneath some projections. Conversely, the inclusion of insurers and policy-oriented financial institutions in the allocation exceeded market expectations. The breakdown of the 360 billion yuan is as follows: 260 billion yuan for the big banks (Agricultural Bank of China receiving 160 billion yuan, ICBC receiving 100 billion yuan); 60 billion yuan for insurance firms (China Life Insurance receiving 35 billion yuan, PICC receiving 15 billion yuan, China Taiping getting 7 billion yuan, and China Reinsurance receiving 3 billion yuan); and 40 billion yuan for policy-oriented financial institutions (Export-Import Bank of China receiving 30 billion yuan, and Sinosure receiving 10 billion yuan). Under the earlier framework that suggested 300 billion yuan in special bonds for the banks, this latest distribution implies a slightly lower amount reaching the banking sector than originally signaled.

Understanding the rationale behind replenishing core Tier 1 capital requires a closer look at bank regulatory dynamics. Core Tier 1 capital is directly tied to metrics such as capital adequacy ratios and interest rate risk in the banking book. However, generating this capital internally has become increasingly difficult under current conditions. Core Tier 1 capital mainly comprises ordinary shares and retained earnings. With net interest margins under pressure, relying on retained earnings to build capital has proven to be a challenging path. Industry-wide data reflects this friction: while capital adequacy and Tier 1 capital ratios have grown substantially since 2014, the core Tier 1 capital adequacy ratio has largely remained flat, hovering around the 10-11% range.

On the other hand, banks face rigid requirements for core capital when it comes to business expansion and risk management. Viewing this through two key regulatory indicators: First, the core Tier 1 capital adequacy ratio, calculated as net core Tier 1 capital divided by risk-weighted assets, determines the maximum scale of business a bank can operate. Expanding that capacity would empower banks to increase credit supply and provide stronger support for the real economy. Second, the interest rate risk in the banking book, measured by changes in economic value of equity (Delta EVE) relative to Tier 1 capital, defines the permissible scale of Delta EVE a bank can absorb in response to interest rate shocks. This, in turn, sets the upper bound for their capacity to underwrite government bonds, especially those with ultra-long maturities.

For insurance companies, the capital injection carries different implications, mainly in guiding long-term capital into the market and elevating the influence of leading insurers. The urgency to relieve regulatory pressure appears less acute for these top-tier firms. The relevant indicator here is the core solvency adequacy ratio, computed as core capital divided by minimum capital. A reading below 60% would place an insurer on the regulator's priority review list. Still, the sector shows clear internal divergence, with headline insurers showing limited strain. Take China Life Insurance, a beneficiary in this round, as an example. Its core solvency adequacy ratio stood at a comfortable 156.8% in the first half of 2026, far above the regulatory floor. This suggests that the injection is more aligned with encouraging long-term capital deployment and strengthening the market position of major insurers.

The impact of this capital injection can be gauged from a quantitative perspective. On core Tier 1 capital adequacy, using mid-2026 disclosures as a baseline, Agricultural Bank of China's ratio is projected to rise from roughly 10.80% to 11.41%, while ICBC's is expected to move from approximately 13.21% to 13.54%. Turning to ultra-long bond absorption, an additional 260 billion yuan in Tier 1 capital for the large banks, under the 15% regulatory cap on Delta EVE relative to Tier 1 capital, would translate into an incremental Delta EVE allowance of 39 billion yuan. With the weighted average duration of 30-year government bonds standing at around 21.51 years, and assuming the newly available capacity is fully deployed toward 30-year government bonds, the potential increase in holdings is estimated at approximately 80.6 billion yuan.

As with any forward-looking analysis, certain risks should be kept in view. Data collection may contain omissions or deviations, bond market conditions could shift in unanticipated ways, and the assumptions underpinning these projections carry inherent margins of error.